Predicting Response to Risperidone and Olanzapine Switch in Schizophrenia

Phase 4, randomised, double-blind trial of olanzapine in schizophrenia, schizoaffective disorder and schizophreniform disorder (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not Early Onset… Started May 2006; status: completed.